QGEN

As of 2026-10-26, QGEN scores 59out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. QGEN trades at $50.37, within its fair-value band.

QGEN scores 59 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 59. Its strongest factor is volume at 73 (strong), where trading volume confirms genuine accumulation, followed by value at 70. The weakest is quality at 43, where earnings-quality metrics lag. Among Healthcare stocks it ranks in roughly the top 15% of the Healthcare names the model scores.

On valuation, QGEN is priced around the middle of its recent range. The blended composite before the macro overlay was 60. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on QGEN, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where QGEN sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for QGEN runs $40.25–$58.55. Current price $50.37 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.